[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651634":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":32,"locations":40,"responsibleParty":82,"collaborators":11,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":11,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":11,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":105,"whyStopped":11,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL",null,[13],"Drug: Golcadomide",{"label":15,"type":10,"description":11,"interventionNames":16},"Group B",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Group C",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Golcadomide","Specified dose on specified days",[9,15,18],[27,28],"BMS-986369","CC-99282",[30],{"name":5,"affiliation":5,"role":31},"STUDY_DIRECTOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":39,"role":35,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[41,57,70],{"facility":42,"status":11,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Local Institution - 0003","Chandler","Arizona","85225","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-111.84125,33.30616,{"lat":52,"lon":51},[55],{"name":56,"role":35,"phone":11,"phoneExt":11,"email":11},"Site 0003",{"facility":58,"status":11,"city":59,"state":60,"zip":61,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Local Institution - 0002","Miami Lakes","Florida","33014",{"type":49,"coordinates":63},[64,65],-80.30866,25.90871,{"lat":65,"lon":64},[68],{"name":69,"role":35,"phone":11,"phoneExt":11,"email":11},"Site 0002",{"facility":71,"status":11,"city":72,"state":60,"zip":73,"country":46,"countryCode":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Local Institution - 0001","Orlando","32809-3017",{"type":49,"coordinates":75},[76,77],-81.37924,28.53834,{"lat":77,"lon":76},[80],{"name":81,"role":35,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":83,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100651634","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-safety-of-golcadomide-in-participants-with-severe-renal-impairment-and-end-stage-renal-disease-compared-with-participants-with-normal-renal-function-100651634",false,"NCT07763418","A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function","A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function","Inclusion Criteria:\n\n* Participant must have severe renal impairment (RI).\n* Participant must have end-stage renal disease (ESRD).\n* Participant must be healthy male and female participants not of childbearing potential between 18 and 84 years of age (inclusive) with a BMI between 18 and 40 kg\u002Fm2, (inclusive) at screening.\n\nExclusion Criteria:\n\n* Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).\n* Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study\n* Known or suspected active autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",true,"ALL","18 Years","84 Years",{"count":96,"type":97},30,"ESTIMATED","INTERVENTIONAL",[100],"PHASE1","The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.",[103],"Kidney Failure, Chronic",[23],"NOT_YET_RECRUITING","2026-08-10",{"date":108,"type":109},"2026-08-13","ACTUAL",{"date":111,"type":97},"2026-08-24",{"date":113,"type":97},"2026-12-28",{"name":5,"class":6},3]